VTEU awarded nine contracts from NIAID worth $945 million
The contracts were awarded for the development of a new institution and to expand the VTEU's ability to conduct research around the world, including settings with scarce resources.
The contracts will be funded by the National Institute of Allergy and Infectious Disease, part of the National Institutes of Health, and are estimated to be worth up to $135 million per year for seven years.
"The VTEUs have been an invaluable resource for testing important vaccines and treatments against deadly emerging infectious disease threats," NIAID Director Anthony S. Fauci said. "Through these new awards, we are increasing the network's capacity to study infectious diseases where they are endemic. This will allow us to learn more about the origin and evolution of emerging diseases and also improve the evaluation of diagnostics along with potential vaccines and treatments."
The VTEU was established in 1962. As a network, it has conducted hundreds of clinical trials to fight off a number of infectious diseases, including influenza, anthrax, cholera, malaria, tuberculosis, pneumonia and pertussis. The expansion will allow the VTEU to conduct research more quickly, helping in the fight against global health concerns.
"Launching and obtaining results from such studies quickly is possible because the VTEUs have proved that they can rapidly enroll large numbers of participants," Fauci said. "This agility is especially important for testing vaccines designed to counteract emerging infectious diseases of public health concern."